BC018465 Inhibitors
Chemical inhibitors of BC018465 function through various mechanisms to decrease its activity. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), and by impeding PI3K, they can reduce the activity of downstream protein kinase B (Akt). Given that Akt is often responsible for phosphorylating a myriad of proteins, its inhibition can directly lead to a decrease in BC018465 activity, assuming BC018465 is one such protein affected by Akt. Similarly, Rapamycin acts on the mechanistic target of rapamycin (mTOR), a central molecule in the mTOR signaling pathway. The inhibition of mTOR by Rapamycin would prevent the activation of BC018465 if it is reliant on signals that are typically conveyed through mTOR. U0126 targets MEK1/2, which are upstream of ERK1/2 kinases. The inhibition of MEK1/2 consequently leads to a decrease in ERK1/2 activity, and if BC018465's function is contingent on ERK1/2 phosphorylation, U0126 would result in the diminishment of its activity.
On another front, SB203580 specifically inhibits p38 MAP kinase, leading to a decrease in the phosphorylation of substrates involved in the p38 MAPK stress response pathway. BC018465 activity would decrease if it is part of this pathway. Staurosporine broadly targets various kinases, which could lead to a widespread reduction in kinase activity, including those that might phosphorylate BC018465. PP2 focuses on inhibiting Src family tyrosine kinases, which can interrupt tyrosine phosphorylation-dependent pathways, and decrease BC018465 activity if it is regulated by Src kinases. PD168393, an irreversible inhibitor of EGFR tyrosine kinase, would lead to a decrease in BC018465 activity if it is regulated by EGFR signaling. In a similar vein, SP600125 inhibits JNK, which is involved in stress responses and apoptosis, and would reduce BC018465 function if it is part of the JNK pathway.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways including those regulating protein kinase B (Akt). Inhibition of PI3K leads to decreased Akt activity. As Akt can positively regulate many proteins through phosphorylation, its inhibition can result in decreased function of BC018465 if BC018465 is Akt-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, working similarly to Wortmannin. By inhibiting PI3K, LY294002 reduces Akt signaling, potentially leading to reduced phosphorylation and activity of BC018465, assuming BC018465 is downstream of Akt. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mechanistic target of rapamycin (mTOR), a kinase that is part of mTOR signaling pathway. If BC018465 operates downstream of mTOR, its inhibition would prevent the activation of BC018465 by upstream signals that are mediated through mTOR. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits mitogen-activated protein kinase kinase (MEK1/2), which are upstream of extracellular signal-regulated kinases (ERK1/2). By inhibiting MEK1/2, U0126 can decrease ERK1/2 activity, which could lead to a reduction in BC018465 activity if BC018465 is a substrate of ERK1/2 or is otherwise ERK1/2-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor. Inhibiting p38 MAP kinase can reduce the phosphorylation of substrates involved in stress responses, potentially diminishing the function of BC018465 if it is a part of this stress response pathway regulated by p38 MAPK. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor. It can inhibit a wide range of kinases that might phosphorylate BC018465, leading to a decrease in BC018465 activity through broad-spectrum kinase inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 may reduce the tyrosine phosphorylation-dependent signaling pathways, potentially decreasing the activity of BC018465 if it is regulated by Src-mediated phosphorylation. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
PD168393 irreversibly inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Inhibition of EGFR can lead to a reduction in downstream signaling pathways, which could decrease BC018465 activity if BC018465 is part of the EGFR signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK). JNK is involved in stress responses and apoptosis. Inhibition of JNK signaling can lead to decreased function of BC018465 if BC018465 is involved in pathways regulated by JNK activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $199.00 $460.00 $1479.00 | 1 | |
NF449 is a potent and selective inhibitor of the Gs-alpha subunit of G-proteins. Inhibition of Gs-alpha can lead to decreased cyclic AMP (cAMP) levels and reduced protein kinase A (PKA) activity, which may result in decreased function of BC018465 if it is downstream of PKA. | ||||||